INTC
Intel
-- 23.600 TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 SOFI
SoFi Technologies
-- 16.210 SMCI
Super Micro Computer
-- 47.910 
NEWS
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Cellectar Biosciences (NASDAQ: CLRB) announced two presentations on iopofosine I 131 at the 12th International Workshop on Waldenstrom's Macroglobulinemia in Prague.
The first presentation by Dr. Jorge Castillo will showcase a case study of complete central nervous system clearance in a patient with Bing-Neel Syndrome (BNS), a rare complication of Waldenstrom's Macroglobulinemia (WM).
The second presentation by Dr. Andrei Shustov will review topline data from the CLOVER WaM pivotal study, the largest WM study to date in a highly refractory patient population.
Iopofosine I 131, Cellectar's lead product candidate, is a potential first-in-class cancer targeting agent that has demonstrated the ability to cross the blood-brain barrier and shown clinical activity in multiple hematologic malignancies involving the central nervous system.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8164
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call